Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD44 antibody variable domain is fused to CH1 and the other scFv from an anti-CR3 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY